bca protein assay Search Results


bca protein assay kit  (Danaher Inc)
99
Danaher Inc bca protein assay kit
Bca Protein Assay Kit, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bca protein assay kit/product/Danaher Inc
Average 99 stars, based on 1 article reviews
bca protein assay kit - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier
human bcma fc tag protein  (ACROBiosystems)
95
ACROBiosystems human bcma fc tag protein
( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human <t>BCMA</t> Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .
Human Bcma Fc Tag Protein, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human bcma fc tag protein/product/ACROBiosystems
Average 95 stars, based on 1 article reviews
human bcma fc tag protein - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
recombinant human cxcl13  (R&D Systems)
92
R&D Systems recombinant human cxcl13
( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human <t>BCMA</t> Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .
Recombinant Human Cxcl13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human cxcl13/product/R&D Systems
Average 92 stars, based on 1 article reviews
recombinant human cxcl13 - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
murine cxcl13  (R&D Systems Hematology)
93
R&D Systems Hematology murine cxcl13
( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human <t>BCMA</t> Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .
Murine Cxcl13, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/murine cxcl13/product/R&D Systems Hematology
Average 93 stars, based on 1 article reviews
murine cxcl13 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
bca protein assay kit  (Elabscience Biotechnology)
97
Elabscience Biotechnology bca protein assay kit
( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human <t>BCMA</t> Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .
Bca Protein Assay Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bca protein assay kit/product/Elabscience Biotechnology
Average 97 stars, based on 1 article reviews
bca protein assay kit - by Bioz Stars, 2026-04
97/100 stars
  Buy from Supplier
bca protein assay kit  (tiangen biotech co)
96
tiangen biotech co bca protein assay kit
( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human <t>BCMA</t> Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .
Bca Protein Assay Kit, supplied by tiangen biotech co, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bca protein assay kit/product/tiangen biotech co
Average 96 stars, based on 1 article reviews
bca protein assay kit - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier
bca protein assay  (Genesee Scientific)
94
Genesee Scientific bca protein assay
( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human <t>BCMA</t> Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .
Bca Protein Assay, supplied by Genesee Scientific, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bca protein assay/product/Genesee Scientific
Average 94 stars, based on 1 article reviews
bca protein assay - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
human cxcl13  (R&D Systems Hematology)
93
R&D Systems Hematology human cxcl13
( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human <t>BCMA</t> Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .
Human Cxcl13, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cxcl13/product/R&D Systems Hematology
Average 93 stars, based on 1 article reviews
human cxcl13 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
bca assay  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc bca assay
( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human <t>BCMA</t> Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .
Bca Assay, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bca assay/product/Cell Signaling Technology Inc
Average 95 stars, based on 1 article reviews
bca assay - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
biotinylated human bcma protein  (ACROBiosystems)
95
ACROBiosystems biotinylated human bcma protein
Fig. 2 | ISB 2001 optimized architecture and avidity binding increases killing and accelerates synapse formation. a–c, Cytotoxicity of KMS-12-BM cells at different concentrations of CD3 ×DU × CD38 and CD3 × CD38 × DU (a), CD3 × <t>BCMA</t> × DU and CD3 × DU × BCMA (b) and ISB 2001 and CD3 × CD38 × BCMA (c). RDL assays were performed at a 5:1 effector to target ratio for 48 h with purified T cells. Graphs show four-parameter logistic curve fitting with symbols representing mean ± s.d. (n = 6 independent T cell donors from two independent experiments). d–f, T cell activation in a HD- PBMC at different concentrations of CD3 × DU × CD38 and CD3 × CD38 × DU (d), CD3 × BCMA × DU and CD3 × DU × BCMA (e) and ISB 2001 and CD3 × CD38 × BCMA (f). Graphs show four-parameter logistic curve fitting with symbols representing mean ± s.d. (n = 6 independent T cell donors from two independent experiments). g, Cytotoxicity of the KMS-12-BM cell line at different concentrations of ISB 2001, CD3 × BCMA × DU, CD3 × DU × CD38 and the combination of CD3 × BCMA × DU and CD3 × DU × CD38. Graphs show four-parameter logistic curve fitting with symbols representing mean ± s.d.
Biotinylated Human Bcma Protein, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotinylated human bcma protein/product/ACROBiosystems
Average 95 stars, based on 1 article reviews
biotinylated human bcma protein - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

Image Search Results


( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human BCMA Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .

Journal: EMBO Molecular Medicine

Article Title: B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis

doi: 10.1038/s44321-024-00043-z

Figure Lengend Snippet: ( A ) A schematic overview of the time points at which patients receive different treatments before CAR-T infusion. # Patient MG-1 was treated with IVIG 2 g/Kg + intravenous pulse steroid 500 mg* 3days for myasthenia crisis. ( B ) A schematic overview of CAR-T treatment procedure. CAR T-cell kinetics are shown by the CAR copies per μg genomic DNA at serial time points post infusion detected by droplet digital PCR. ( C ) Representative plots showing FACS analysis stained for CAR-T cells with FITC-labeled human BCMA Fc tag protein and APC/Cy7 anti-human CD3 antibody in patient MG-1 at day 10 after CAR T-cell infusion. CAR T-cell percentage in circulating CD3 + T lymphocytes at serial time points after treatment. ( D ) Timelines of patients with cytopenia of grade 3 or higher at baseline and indicated time points after CAR T-cell infusion. BL baseline. Kinetic changes in numbers of circulating total white blood cells, neutrophils, monocytes and platelets. ( E ) Heatmap depicting protein levels of inflammatory mediators in blood following CAR T-cell infusion. Interleukin IL, TNF tumor necrosis factor, IFN interferon, CRP C-reactive protein, PCT procalcitonin. Average levels are normalized from the baseline. .

Article Snippet: Website links for the antibodies used in the flow cytometry are following: PerCP/Cyanine5.5 anti-human CD45 Antibody (Biolegend, 304028): https://www.biolegend.com/en-us/products/percp-cyanine5-5-anti-human-cd45-antibody-4240 ; FITC anti-human CD3 antibody (BD Biosciences, 561802): https://www.bdbiosciences.com/zh-cn/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/fitc-mouse-anti-human-cd3.561802 ; PE/Cyanine7 anti-Human CD4 (BD Biosciences, 560649): https://www.bdbiosciences.com/zh-cn/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/pe-cy-7-mouse-anti-human-cd4.560649 ; APC/Cyanine7 anti-Human CD8 (BD Biosciences, 557834): https://www.bdbiosciences.com/zh-cn/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/apc-cy-7-mouse-anti-human-cd8.557834 ; APC anti-human CD19 Antibody (Biolegend, 302212): https://www.biolegend.com/en-us/products/apc-anti-human-cd19-antibody-715 ; PE anti-human CD16 Antibody (Biolegend, 302056): https://www.biolegend.com/en-us/products/pe-anti-human-cd16-antibody-569 ; PE anti-human CD56 Antibody (Biolegend, 318306): https://www.biolegend.com/en-us/products/pe-anti-human-cd56-ncam-antibody-3796 ; FITC anti-Human CD38 (BD Biosciences, 567147): https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/fitc-mouse-anti-human-cd38.567147 ; PerCP/Cyanine5.5 anti-Human CD27 (BD Biosciences, 560612): https://www.bdbiosciences.com/zh-cn/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/percp-cy-5-5-mouse-anti-human-cd27.560612 ; PerCP anti-Human CD45 (BD Biosciences, 347464): https://www.bdbiosciences.com/zh-cn/products/reagents/flow-cytometry-reagents/clinical-discovery-research/single-color-antibodies-ruo-gmp/percp-mouse-anti-human-cd45.347464 ; APC/Cyanine7 anti-human CD3 Antibody (Biolegend, 344818): https://www.biolegend.com/en-us/products/apc-cyanine7-anti-human-cd3-antibody-6940 ; FITC-labeled human BCMA Fc tag protein (Acrobiosystems, BCA-HF254): https://www.acrobiosystems.cn/P875-FITC-Labeled_Human_BCMA_%7C_TNFRSF17_Protein_Fc_Tag.html .

Techniques: Digital PCR, Staining, Labeling

Fig. 2 | ISB 2001 optimized architecture and avidity binding increases killing and accelerates synapse formation. a–c, Cytotoxicity of KMS-12-BM cells at different concentrations of CD3 ×DU × CD38 and CD3 × CD38 × DU (a), CD3 × BCMA × DU and CD3 × DU × BCMA (b) and ISB 2001 and CD3 × CD38 × BCMA (c). RDL assays were performed at a 5:1 effector to target ratio for 48 h with purified T cells. Graphs show four-parameter logistic curve fitting with symbols representing mean ± s.d. (n = 6 independent T cell donors from two independent experiments). d–f, T cell activation in a HD- PBMC at different concentrations of CD3 × DU × CD38 and CD3 × CD38 × DU (d), CD3 × BCMA × DU and CD3 × DU × BCMA (e) and ISB 2001 and CD3 × CD38 × BCMA (f). Graphs show four-parameter logistic curve fitting with symbols representing mean ± s.d. (n = 6 independent T cell donors from two independent experiments). g, Cytotoxicity of the KMS-12-BM cell line at different concentrations of ISB 2001, CD3 × BCMA × DU, CD3 × DU × CD38 and the combination of CD3 × BCMA × DU and CD3 × DU × CD38. Graphs show four-parameter logistic curve fitting with symbols representing mean ± s.d.

Journal: Nature cancer

Article Title: ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.

doi: 10.1038/s43018-024-00821-1

Figure Lengend Snippet: Fig. 2 | ISB 2001 optimized architecture and avidity binding increases killing and accelerates synapse formation. a–c, Cytotoxicity of KMS-12-BM cells at different concentrations of CD3 ×DU × CD38 and CD3 × CD38 × DU (a), CD3 × BCMA × DU and CD3 × DU × BCMA (b) and ISB 2001 and CD3 × CD38 × BCMA (c). RDL assays were performed at a 5:1 effector to target ratio for 48 h with purified T cells. Graphs show four-parameter logistic curve fitting with symbols representing mean ± s.d. (n = 6 independent T cell donors from two independent experiments). d–f, T cell activation in a HD- PBMC at different concentrations of CD3 × DU × CD38 and CD3 × CD38 × DU (d), CD3 × BCMA × DU and CD3 × DU × BCMA (e) and ISB 2001 and CD3 × CD38 × BCMA (f). Graphs show four-parameter logistic curve fitting with symbols representing mean ± s.d. (n = 6 independent T cell donors from two independent experiments). g, Cytotoxicity of the KMS-12-BM cell line at different concentrations of ISB 2001, CD3 × BCMA × DU, CD3 × DU × CD38 and the combination of CD3 × BCMA × DU and CD3 × DU × CD38. Graphs show four-parameter logistic curve fitting with symbols representing mean ± s.d.

Article Snippet: For binding to CD3εδ, BCMA and CD38, biotinylated human CD3ε&CD3δ protein (Creative Biomart, CD3E & CD3D-377H), biotinylated human CD38 protein (Acrobiosystems, CD8-H82E7) or biotinylated human BCMA protein (Acrobiosystems, BCA-H82E4) were immobilized on a Biotin Capture (CAP) sensor chip (Cytiva) and increasing concentrations of ISB 2001 were flushed onto the immobilized ligand.

Techniques: Binding Assay, Purification, Activation Assay